Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

A new report from leading contract research organisation Novotech has shed light on the current state of play in the global ...

The NCCN 2024 guidelines include recommendations such as chemoradiation and pembrolizumab-based therapies for PD-L1-positive tumors. Treatment options for recurrent or metastatic cervical cancer ...

and PFS compared to concurrent CRT alone for newly diagnosed patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer.

Amtagvi Infusions: A total of 146 patients have been infused with Amtagvi since the first commercial infusion in April 2024, including 25 patients infused in the second quarter, 82 patients infused in ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck ... Stage III-IVA locally ...

and PFS compared to concurrent CRT alone for newly diagnosed patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer. In June 2024, KEYTRUDA in combination with carboplatin and ...

Study Rundown: Cervical cancer is the fourth most common cancer affecting women worldwide. Previous trials have shown that adding pembrolizumab, an anti-PD1 antibody, to chemoradiotherapy may improve ...

Read about a medical student treated at MSK for aggressive cervical cancer who later returned to train alongside MSK surgeons.

The addition of pembrolizumab to modern and high-quality chemoradiotherapy significantly improved overall survival (OS) in patients with locally advanced cervical cancer, according to results from the ...